Eagle Pharmaceuticals (EGRX) Tops Q1 EPS by 22c

Eagle Pharmaceuticals (NASDAQ: EGRX) reported Q1 EPS of ($0.06), $0.22 better than the analyst estimate of ($0.28). Revenue for the quarter came in at $29.6 million versus the consensus estimate of $17.33 million.

Cash and cash equivalents were $78.3 million as of March 31, 2016.

For earnings history and earnings-related data on Eagle Pharmaceuticals (EGRX) click here.

You May Also Be Interested In

• FedEx falls 4% as FY2027 profit forecast misses expectations despite Q4 beat
• Citrini flags overheating concerns as leverage, chip rally weigh on KOSPI
• Cerebras Systems posts 94% revenue jump, announces OpenAI deal